Drugs / HS-10360
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04986436 | Jul 2021 → Jun 2022 | — | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-10360 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04986436 ↗ |
| Route | Oral | “Oral Administered HS-10360” NCT04986436 ↗ |